What are Turn Therapeutics Inc. Common Stock's total assets?

Turn Therapeutics Inc. Common Stock (TTRX) holds $18.6M in total assets.

How much debt does Turn Therapeutics Inc. Common Stock have?

Turn Therapeutics Inc. Common Stock carries $6.0M in total debt against $6.1M of shareholders' equity, a debt-to-equity ratio of 0.98.

How much cash does Turn Therapeutics Inc. Common Stock have?

Turn Therapeutics Inc. Common Stock holds $11.2M in cash and equivalents.

Can Turn Therapeutics Inc. Common Stock cover its short-term obligations?

Its current ratio is 2.23 — current assets exceed current liabilities.

Where does Turn Therapeutics Inc. Common Stock's balance sheet data come from?

Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Turn Therapeutics Inc. Common Stock TTRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q1 '25	Q4 '24
Cash and cash equivalents	$11.22M+121%	$5.08M+63.4%	$3.11M+97.5%	$1.57M+80.2%	$872.6K+10.6%
Prepaid expenses and other current assets	$235.17K+95.5%	$120.3K-36.2%	$188.58K-34.3%	$287.14K+27.4%	$225.33K—
Total current assets	$11.45M+120%	$5.2M+57.7%	$3.29M—	——	$1.1M—
Operating lease right-of-use assets	$67.57K-14.1%	$78.62K-12.1%	$89.42K—	——	$120.45K—
Intangible assets, net	$919.95K-0.2%	$922.17K+1.9%	$904.89K—	——	$821.93K—
Total assets	$18.64M+53.3%	$12.16M+183%	$4.3M—	——	$2.05M—
Operating lease liabilities, current	$47.8K+3.2%	$46.3K+3.3%	$44.83K—	——	$40.66K—
Contract liabilities	$1.44M0.0%	$1.44M0.0%	$1.44M—	——	$1.44M—
Total current liabilities	$5.13M-14.5%	$6M+160%	$2.31M—	——	$707.93K—
Long-term debt	$5.94M—	——	——	——	——
Operating lease liabilities, non-current	$21.54K-36.8%	$34.08K-26.5%	$46.34K—	——	$80.38K—
Operating Lease Liabilities (Total)	——	$80.38K—	——	——	——
Total liabilities	$12.53M+67.6%	$7.48M+97.1%	$3.79M—	——	$2.23M—
Common stock	$500M0.0%	$500M0.0%	$500M—	——	$2.68K—
Additional paid-in capital	$29.48M+4.7%	$28.14M+21.2%	$23.22M—	——	$19.02M—
Retained earnings	-$23.36M-4.3%	-$22.39M+1.2%	-$22.67M—	——	-$19.2M—
Total stockholders' equity	$6.12M+30.5%	$4.69M+830%	$504.02K-38.4%	$818.71K+561%	-$177.43K+57.2%
Total liabilities and stockholders' equity	$18.64M+53.3%	$12.16M+183%	$4.3M—	——	$2.05M—
Net Investment in Lease	$67.57K-14.1%	$78.62K-12.1%	$89.42K—	——	$120.45K—
Deferred contract costs	$6.2M+4.0%	$5.96M—	——	——	——
Other intangible assets—net	$919.95K-0.2%	$922.17K+1.9%	$904.89K—	——	$821.93K—
Operating lease right-of-use assets	$67.57K-14.1%	$78.62K-12.1%	$89.42K—	——	$120.45K—
Operating Lease Right-of-Use Assets in Other Assets	$67.57K-14.1%	$78.62K-12.1%	$89.42K—	——	$120.45K—
Accrued liabilities and other current	$2.32M-20.9%	$2.93M+29.3%	$2.26M—	——	$667.27K—
Accrued Progress Collections and Price Adjustments	$1.44M0.0%	$1.44M0.0%	$1.44M—	——	$1.44M—
Derivative Liability, Current	$2.77M-8.6%	$3.03M—	——	——	——
Derivative Liabilities - Fair Value	$2.77M-8.6%	$3.03M—	——	——	——
Contract Liabilities, Non-Current	$1.44M0.0%	$1.44M0.0%	$1.44M—	——	$1.44M—
Debt Instrument Face Amount	$7M—	——	——	——	——
Debt Maturity - 2027	$3.11M—	——	——	——	——
Deferred revenue, net of current portion	$1.44M0.0%	$1.44M0.0%	$1.44M—	——	$1.44M—
Total debt	$6.01M+7,372%	$80.38K-11.8%	$91.17K—	——	$121.04K—
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.00—	——	$0.00—
Common Stock Shares Issued	$29.79M+1.2%	$29.45M+5.1%	$28.02M—	——	$26.85M—
Common Stock Shares Outstanding	$1.95M-75.9%	$8.08M+42.5%	$5.67M—	——	$3.88M—
Convertible Preferred Stock Authorized Shares	$100M—	——	$100M—	——	——
Additional paid-in capital	$29.48M+4.7%	$28.14M+21.2%	$23.22M—	——	$19.02M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2.98K+1.2%	$2.94K+5.0%	$2.8K—	——	$2.68K—
Stockholders' Equity Note, Subscriptions Receivable	——	$1.07M+1,930%	$52.7K—	——	——
Number of Exercisable Options	$1.63M—	——	$1.63M—	——	——
Preferred Stock Par Value Per Share	$0.00—	——	$0.00—	——	——
Share-Based Payment Award Options Outstanding - Number	$1.94M0.0%	$1.94M+12.1%	$1.73M—	——	$1.68M—
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$1.2M—	——	$305.35K—	——	——
Warrants and Rights Outstanding	1.2M—	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	3.30.0%	3.3+37.0%	2.4—	——	2.3—
Cash FDIC Insured Amount	$10.8M—	——	$2.57M—	——	$4.5M—
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1	$5.03—	——	——	——	——
Class of Warrant or Right, Outstanding	$1.19M—	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$0—	——	$0—
Common stock, shares authorized (in shares)	$500M0.0%	$500M0.0%	$500M—	——	$40M—
Common stock, shares issued (in shares)	$29.79M+1.2%	$29.45M+5.1%	$28.02M—	——	$26.85M—
Common Stock, Shares, Outstanding	$29.79M+1.2%	$29.45M+5.1%	$28.02M—	——	$26.85M—
Contingent Consideration Classified As Equity Fair Value Disclosure	20,000,000%0.0%	20,000,000%—	——	——	——
Debt issuances	$7M—	——	——	——	——
Debt Instrument, Unamortized Discount, Noncurrent	$1.24M—	——	——	——	——
Unrecognized compensation cost related to non-vested awards	$1.2M—	——	$305.35K—	——	——
Gross Final Payment Fee	$262.5K—	——	——	——	——
2028	$1.3M—	——	——	——	——
2029	$3.11M—	——	——	——	——
2030	$2.86M—	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0—	——	$0—	——	——
Preferred Stock, Shares Authorized	$100M—	——	$100M—	——	——
Present Value Discount On Final Payment Fee	$87.93K—	——	——	——	——
Security Deposit	$8.58K0.0%	$8.58K0.0%	$8.58K—	——	$8.58K—
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$1.63M—	——	$1.63M—	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$1.94M0.0%	$1.94M+12.1%	$1.73M—	——	$1.68M—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$3.260.0%	$3.26+37.0%	$2.38—	——	$2.28—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$1.95M-75.9%	$8.08M+42.5%	$5.67M—	——	$3.88M—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$3.88—	——	$2.53—	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$1.95M—	——	$5.67M—	——	——
Shares Issued Price Per Share	——	$4.95—	——	——	——
Working Capital	$9.1M—	——	$980K—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Turn Therapeutics Inc. Common Stock's total assets?: Turn Therapeutics Inc. Common Stock (TTRX) holds $18.6M in total assets.
How much debt does Turn Therapeutics Inc. Common Stock have?: Turn Therapeutics Inc. Common Stock carries $6.0M in total debt against $6.1M of shareholders' equity, a debt-to-equity ratio of 0.98.
How much cash does Turn Therapeutics Inc. Common Stock have?: Turn Therapeutics Inc. Common Stock holds $11.2M in cash and equivalents.
Can Turn Therapeutics Inc. Common Stock cover its short-term obligations?: Its current ratio is 2.23 — current assets exceed current liabilities.
Where does Turn Therapeutics Inc. Common Stock's balance sheet data come from?: Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.